Drug intelligence / Profile preview

AXR-159

Development stage: Phase 2
Lead developer: CS Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

AXR-159 is a small molecule ophthalmic solution developed by AxeroVision for the treatment of dry eye disease (DED). It acts as an antagonist of integrin alpha4beta1 and alpha4beta7 (CD49d), targeting inflammatory pathways implicated in DED. Preclinical data suggest that AXR-159 interrupts multiple points in the immune cycle associated with ocular surface inflammation, potentially providing rapid and broad relief from dry eye symptoms. In clinical studies, it has demonstrated a fast onset of action and global improvement in ocular surface staining. The drug is currently in phase II clinical development for dry eye disease[1][2][3][4][6][7].

Targets

α4β7 (Integrin alpha-4 beta-7 heterodimer)α4β1 (Integrin α4β1)ITGA4 (Integrin alpha-4)

Beyond the preview

Go deeper on AXR-159.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXR-159.

Explore the full profile